CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Kyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoo
Cancer Research and Treatment. 2020;52(1):254-262.   Published online 2019 July 9    DOI: https://doi.org/10.4143/crt.2019.190

Excel Download

Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Annals of Oncology. 2019;30:ix55   Crossref logo
Link1 Link2 Link3 Link4

Su1157 EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
Gastroenterology. 2020;158(6):S-527   Crossref logo
Link1 Link2

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Cancer Research and Treatment. 2020;52(1):254-262   Crossref logo
Link1 Link2 Link3

Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer
Japanese Journal of Clinical Oncology. 2022;   Crossref logo
Link1 Link2

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
Journal of Cancer Research and Clinical Oncology. 2020;147(5):1529-1536   Crossref logo
Link1 Link2 Link3

Incidence Of Neutropenia In Patients Receiving Either Nab-Paclitaxel Plus Gemcitabine Or Folfirinox As First-Line Treatment For Metastatic Pancreatic Adenocarcinoma
Value in Health. 2016;19(3):A141   Crossref logo
Link1 Link2

<p>Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma</p>
Cancer Management and Research. 2020;Volume 12:12657-12666   Crossref logo
Link1 Link2

Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less
Annals of Oncology. 2019;30:iv83-iv84   Crossref logo
Link1 Link2 Link3

<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>
Cancer Management and Research. 2020;Volume 12:10271-10278   Crossref logo
Link1 Link2

Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis
Chemotherapy. 2021;66(3):58-64   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.